Loading...
•
Oct 25, 2024
Medtronic Q2 2025 Earnings Report
Medtronic's Q2 2025 financial results demonstrated strong execution and exceeded expectations, leading to raised guidance.
Key Takeaways
Medtronic reported a strong second quarter in fiscal year 2025, with revenue of $8.4 billion, a 5.3% increase as reported and 5.0% organic. GAAP diluted EPS was $0.99, while non-GAAP diluted EPS reached $1.26. The company has raised its full-year guidance for both organic revenue growth and EPS.
Revenue increased by 5.3% as reported, reaching $8.4 billion, with 5.0% organic growth.
GAAP diluted earnings per share (EPS) was $0.99, and non-GAAP diluted EPS was $1.26.
The company raised its FY25 organic revenue growth and EPS guidance.
Innovation is driving sustained growth across multiple franchises, including TAVR, PFA, leadless pacemakers, diabetes, spine, and neuromodulation.
Medtronic
Medtronic
Medtronic Revenue by Segment
Medtronic Revenue by Geographic Location
Revenue by Segment
Cardiac Rhythm & HF Revenue
CapyFin.comStructural Heart & Aortic Revenue
CapyFin.comCoronary & Peripheral Vascular Revenue
CapyFin.comCranial & Spinal Technologies Revenue
CapyFin.comSpecialty Therapies Revenue
CapyFin.comNeuromodulation Revenue
CapyFin.comSurgical & Endoscopy Revenue
CapyFin.comAcute Care & Monitoring Revenue
CapyFin.comDiabetes Revenue
CapyFin.comOther Segment Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Medtronic raised its FY25 organic revenue growth guidance to 4.75% to 5% and non-GAAP EPS guidance to $5.44 to $5.50.
Positive Outlook
- FY25 organic revenue growth guidance raised to 4.75% to 5%.
- FY25 diluted non-GAAP EPS guidance raised to $5.44 to $5.50.
- Expect to report high-single digit adjusted EPS growth in the back half of our fiscal year.
- Focus on underlying margin improvement.
- Innovation driving growth.
Challenges Ahead
- Includes an estimated -5% impact from foreign currency exchange based on recent rates.
- SE year-over-year results were affected by a difficult comparison from prior year supply recovery in Surgical.
- SE results were affected by a difficult comparison from prior year increased sequentially.
- Cardiac Ablation Solutions had flat results as strong growth of the PulseSelect™ pulsed field ablation (PFA) system offset declines in cryoablation.
- Other revenue decreased (38.9)%
Revenue & Expenses
Visualization of income flow from segment revenue to net income